Enhancing Effect of Newcastle Disease Virus in Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer
|School||Dalian Medical University|
|Keywords||Newcastle disease virus Non-small cell lung cancer Drug therapy Vinorelbine Carboplatin|
Objective : To investigate the Newcastle disease virus in Ⅲ, Ⅳ stage non-small cell lung cancer (NSCLC) chemotherapy and its possible mechanism of anti-tumor effect . Methods: The pathology or cytology confirmed Ⅲ, Ⅳ NSCLC were randomly divided into experimental and control groups . Experimental group, 73 cases , the use of Newcastle disease virus vinorelbine and carboplatin chemotherapy ; control group 73 cases , the use of vinorelbine and carboplatin chemotherapy. Every 28 days for a cycle of four cycles of chemotherapy . Evaluated every two cycles , monitoring before and after treatment in peripheral blood leukocytes (WBC), hemoglobin (HB), lymphocyte subsets, platelet (PLT) change and the two chemotherapy toxicity , KPS ( health evaluation ) of difference . Results : The experimental group and control group response rate was 47.95% and 42.47% (P <0.05). Experimental group, gastrointestinal reactions and bone marrow suppression was significantly reduced compared with the control group , there was significant difference between the two groups (P <0.05). KPS score of the experimental group was significantly higher. CD4/CD8 experimental group before and after treatment were 1.30 ± 0.94 and 1.59 ± 1.17; CD4/CD8 the control group before and after treatment were 1.45 ± 0.90 and 1.06 ± 0.48, two groups, the difference was statistically significant (P <0.05). And the experimental group was significantly higher KPS score after chemotherapy (P <0.05). Conclusion: Newcastle disease virus vinorelbine (NVB) carboplatin (CBP) in the treatment of stage Ⅲ, Ⅳ non-small cell lung cancer (NSCLC) significantly enhanced efficacy , reduce toxicity , synergistic anticancer chemotherapy , improve immune function and improve patient health effect.